Tenaya Therapeutics Inc

NASDAQ TNYA

Data sourced from

and

Download Data

Tenaya Therapeutics Inc Net Operating Profit After Tax (NOPAT) 1 year YoY Change (%) for the quarter ending September 30, 2023: 9.73%

Tenaya Therapeutics Inc Net Operating Profit After Tax (NOPAT) 1 year YoY Change (%) is 9.73% for the quarter ending September 30, 2023, a 115.33% change year over year. Net Operating Profit After Taxes (NOPAT) is a financial metric that represents a company's operating profit after deducting taxes. It is calculated by multiplying the earnings before interest and taxes (EBIT) by (1 - tax rate). NOPAT provides insights into the company's profitability from its core operations while accounting for the impact of taxes. It is useful for assessing the company's operating performance and comparing profitability across different tax environments. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Tenaya Therapeutics Inc Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2023 was -26,839,462.43, a 10.81% change year over year.
Tenaya Therapeutics Inc Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2022 was -30,092,739.05, a -142.50% change year over year.
Tenaya Therapeutics Inc Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2021 was -12,409,364.48, a -46.41% change year over year.
Tenaya Therapeutics Inc Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2020 was -8,475,765.33.

NASDAQ: TNYA

Tenaya Therapeutics Inc

CEO	Mr. Faraz Ali M.B.A.
IPO Date	July 30, 2021
Location	United States
Headquarters	171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees	140
Sector	Healthcare
Industry	Biotechnology

Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Key trends